English

NUTRA PHARMA CORP

EDGAR

NPHC Quarterly report (10-Q) · filed 2026-08-19

Annual consolidated revenue for 2025: about USD 257.6K, using the latest reported figures. The previous period, 2024, was about USD 246.3K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

34.5 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 34463 USD Source

Operating margin

-1,263.57%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -435464 USD Source
Revenue: 34463 USD Source

Operating cash flow

-251 thousand USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -579014 USD Source
Operating Cash Flow: -327791 USD Source

Cash and cash equivalents: 12.2 thousand USD 2025-12-31 Source
Exact value

12181 USD
Long-term debt including current maturities: 12.6 million USD 2026-06-30 Source
Exact value

12573897 USD
Shares outstanding: 7.16 billion shares 2026-06-30 Source
Exact value

7159727214 shares

Reported share-count change

0.85% · 60 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

7099727214 shares · 2025-06-30· Source
7159727214 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

161 thousand USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 70242 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 257612 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 228748 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 27246 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 34463 USD · 2026-04-01 – 2026-06-30 Source

Net income

-5.42 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -523520 USD · 2025-07-01 – 2025-09-30 Source
Net income: -2047392 USD · 2025-01-01 – 2025-12-31 Source
Net income: -1558866 USD · 2025-01-01 – 2025-09-30 Source
Net income: -459675 USD · 2026-01-01 – 2026-03-31 Source
Net income: -3948772 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-1.05 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -944146 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -693376 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -1163964 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -944146 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -327791 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -579014 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -327791 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

26.1 thousand USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Capital expenditure: 26052 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 26052 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 26052 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 26052 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 26052 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 26052 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 26052 USD · 2025-01-01 – 2025-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-08-19.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 11 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2025-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2025-12-31
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+4.6%

Prior period

USD 246,309

2024-01-01 – 2024-12-31
Current period

USD 257,612

2025-01-01 – 2025-12-31

Exact inputs and evidence

257612 − 246309 = 11303 USD

246309 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
257612 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · NUTRA PHARMA CORP · 2025-12-31 NUTRA PHARMA CORP (edgar:1119643) Year-over-year change in Revenue: 11303 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 257612 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#925843 Filing: 000149315226024641 Input fundies:Revenue: 246309 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#926498 Filing: 000149315226024641
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 761,729

Prior period

−USD 1.29 million

2024-01-01 – 2024-12-31
Current period

−USD 2.05 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-2047392 − -1285663 = -761729 USD

-1285663 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-2047392 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · NUTRA PHARMA CORP · 2025-12-31 NUTRA PHARMA CORP (edgar:1119643) Year-over-year change in Net income: -761729 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -2047392 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1024047 Filing: 000149315226024641 Input fundies:NetIncome: -1285663 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1024415 Filing: 000149315226024641
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 740,005

Prior period

−USD 423,959

2024-01-01 – 2024-12-31
Current period

−USD 1.16 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-1163964 − -423959 = -740005 USD

-423959 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-1163964 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · NUTRA PHARMA CORP · 2025-12-31 NUTRA PHARMA CORP (edgar:1119643) Year-over-year change in Operating cash flow: -740005 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1163964 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1045508 Filing: 000149315226024641 Input fundies:OperatingCashFlow: -423959 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1045971 Filing: 000149315226024641
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 257,612 100% of revenue
Operating costs Derived USD 1.72 million 668% of revenue
Operating income −USD 1.46 million −568% of revenue
Tax, interest and other Derived USD 585,054 227% of revenue
Net income −USD 2.05 million −795% of revenue

Cash

Operating cash flow −USD 1.16 million −452% of revenue
Capital expenditure USD 26,052 10% of revenue
Free cash flow Derived −USD 1.19 million −462% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 1,314% of revenue.
2017 Operating loss: operating costs were 1,242% of revenue.
2018 Operating loss: operating costs were 1,539% of revenue.
2019 Operating loss: operating costs were 1,278% of revenue.
2020 Operating loss: operating costs were 1,882% of revenue.
2021 Operating loss: operating costs were 2,135% of revenue.
2022 Operating loss: operating costs were 1,408% of revenue.
2023 Operating loss: operating costs were 531% of revenue.
2024 Operating loss: operating costs were 457% of revenue.
2025 Operating loss: operating costs were 668% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	168356	2211872 Derived	-2043516	1404097 Derived	-3447613	-1359880 Derived	Source 2016-01-01 – 2016-12-31: 168356 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -2043516 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -3447613 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -1356498 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 3382 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	120979	1502919 Derived	-1381940	2646808 Derived	-4028748	-1147460 Derived	Source 2017-01-01 – 2017-12-31: 120979 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -1381940 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -4028748 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -1138347 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 9113 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	130596	2009458 Derived	-1878862	2005833 Derived	-3884695	Unavailable	Source 2018-01-01 – 2018-12-31: 130596 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -1878862 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -3884695 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -999949 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	104393	1334286 Derived	-1229893	5361549 Derived	-6591442	Unavailable	Source 2019-01-01 – 2019-12-31: 104393 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -1229893 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -6591442 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -743659 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	51897	976844 Derived	-924947	-155763 Derived	-769184	-883991 Derived	Source 2020-01-01 – 2020-12-31: 51897 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -924947 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -769184 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -878086 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 5905 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	97735	2086180 Derived	-1988445	11107076 Derived	-13095521	-1783512 Derived	Source 2021-01-01 – 2021-12-31: 97735 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -1988445 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -13095521 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -1744469 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 39043 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	145800	2053204 Derived	-1907404	-10084275 Derived	8176871	-820425 Derived	Source 2022-01-01 – 2022-12-31: 145800 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -1907404 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: 8176871 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -762432 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 57993 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	205564	1092543 Derived	-886979	506377 Derived	-1393356	Unavailable	Source 2023-01-01 – 2023-12-31: 205564 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -886979 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -1393356 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -550036 USD Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	246309	1124730 Derived	-878421	407242 Derived	-1285663	Unavailable	Source 2024-01-01 – 2024-12-31: 246309 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -878421 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -1285663 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -423959 USD Inspect Operating Cash Flow Open source
2025 2025-01-01 – 2025-12-31	257612	1719950 Derived	-1462338	585054 Derived	-2047392	-1190016 Derived	Source 2025-01-01 – 2025-12-31: 257612 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -1462338 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -2047392 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -1163964 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 26052 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 257.6K 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	168356	Revenue: 168356 Open source
20172017-12-31	Revenue	120979	Revenue: 120979 Open source
20182018-12-31	Revenue	130596	Revenue: 130596 Open source
20192019-12-31	Revenue	104393	Revenue: 104393 Open source
20202020-12-31	Revenue	51897	Revenue: 51897 Open source
20212021-12-31	Revenue	97735	Revenue: 97735 Open source
20222022-12-31	Revenue	145800	Revenue: 145800 Open source
20232023-12-31	Revenue	205564	Revenue: 205564 Open source
20242024-12-31	Revenue	246309	Revenue: 246309 Open source
20252025-12-31	Revenue	257612	Revenue: 257612 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

4.6% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	-42.2%	Revenue: 168356 Open source Revenue: 291302 Open source
20172017-12-31	Year over year	-28.1%	Revenue: 120979 Open source Revenue: 168356 Open source
20182018-12-31	Year over year	7.9%	Revenue: 130596 Open source Revenue: 120979 Open source
20192019-12-31	Year over year	-20.1%	Revenue: 104393 Open source Revenue: 130596 Open source
20202020-12-31	Year over year	-50.3%	Revenue: 51897 Open source Revenue: 104393 Open source
20212021-12-31	Year over year	88.3%	Revenue: 97735 Open source Revenue: 51897 Open source
20222022-12-31	Year over year	49.2%	Revenue: 145800 Open source Revenue: 97735 Open source
20232023-12-31	Year over year	41%	Revenue: 205564 Open source Revenue: 145800 Open source
20242024-12-31	Year over year	19.8%	Revenue: 246309 Open source Revenue: 205564 Open source
20252025-12-31	Year over year	4.6%	Revenue: 257612 Open source Revenue: 246309 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -567.7% 2025

Net margin -794.8% 2025

Free cash flow margin -461.9% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-1,213.8%	Operating Income: -2043516 Open source Revenue: 168356 Open source
20172017-12-31	Operating margin	-1,142.3%	Operating Income: -1381940 Open source Revenue: 120979 Open source
20182018-12-31	Operating margin	-1,438.7%	Operating Income: -1878862 Open source Revenue: 130596 Open source
20192019-12-31	Operating margin	-1,178.1%	Operating Income: -1229893 Open source Revenue: 104393 Open source
20202020-12-31	Operating margin	-1,782.3%	Operating Income: -924947 Open source Revenue: 51897 Open source
20212021-12-31	Operating margin	-2,034.5%	Operating Income: -1988445 Open source Revenue: 97735 Open source
20222022-12-31	Operating margin	-1,308.2%	Operating Income: -1907404 Open source Revenue: 145800 Open source
20232023-12-31	Operating margin	-431.5%	Operating Income: -886979 Open source Revenue: 205564 Open source
20242024-12-31	Operating margin	-356.6%	Operating Income: -878421 Open source Revenue: 246309 Open source
20252025-12-31	Operating margin	-567.7%	Operating Income: -1462338 Open source Revenue: 257612 Open source
20162016-12-31	Net margin	-2,047.8%	Net Income: -3447613 Open source Revenue: 168356 Open source
20172017-12-31	Net margin	-3,330.1%	Net Income: -4028748 Open source Revenue: 120979 Open source
20182018-12-31	Net margin	-2,974.6%	Net Income: -3884695 Open source Revenue: 130596 Open source
20192019-12-31	Net margin	-6,314.1%	Net Income: -6591442 Open source Revenue: 104393 Open source
20202020-12-31	Net margin	-1,482.1%	Net Income: -769184 Open source Revenue: 51897 Open source
20212021-12-31	Net margin	-13,399%	Net Income: -13095521 Open source Revenue: 97735 Open source
20222022-12-31	Net margin	5,608.3%	Net Income: 8176871 Open source Revenue: 145800 Open source
20232023-12-31	Net margin	-677.8%	Net Income: -1393356 Open source Revenue: 205564 Open source
20242024-12-31	Net margin	-522%	Net Income: -1285663 Open source Revenue: 246309 Open source
20252025-12-31	Net margin	-794.8%	Net Income: -2047392 Open source Revenue: 257612 Open source
20162016-12-31	Free cash flow margin	-807.7%	Revenue: 168356 Open source Operating Cash Flow: -1356498 Open source Capital Expenditure: 3382 Open source
20172017-12-31	Free cash flow margin	-948.5%	Revenue: 120979 Open source Operating Cash Flow: -1138347 Open source Capital Expenditure: 9113 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 130596 Open source Operating Cash Flow: -999949 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 104393 Open source Operating Cash Flow: -743659 Open source
20202020-12-31	Free cash flow margin	-1,703.4%	Revenue: 51897 Open source Operating Cash Flow: -878086 Open source Capital Expenditure: 5905 Open source
20212021-12-31	Free cash flow margin	-1,824.8%	Revenue: 97735 Open source Operating Cash Flow: -1744469 Open source Capital Expenditure: 39043 Open source
20222022-12-31	Free cash flow margin	-562.7%	Revenue: 145800 Open source Operating Cash Flow: -762432 Open source Capital Expenditure: 57993 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 205564 Open source Operating Cash Flow: -550036 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 246309 Open source Operating Cash Flow: -423959 Open source
20252025-12-31	Free cash flow margin	-461.9%	Revenue: 257612 Open source Operating Cash Flow: -1163964 Open source Capital Expenditure: 26052 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -1.2M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-1356498	Operating Cash Flow: -1356498 Open source
20172017-12-31	Operating cash flow	-1138347	Operating Cash Flow: -1138347 Open source
20182018-12-31	Operating cash flow	-999949	Operating Cash Flow: -999949 Open source
20192019-12-31	Operating cash flow	-743659	Operating Cash Flow: -743659 Open source
20202020-12-31	Operating cash flow	-878086	Operating Cash Flow: -878086 Open source
20212021-12-31	Operating cash flow	-1744469	Operating Cash Flow: -1744469 Open source
20222022-12-31	Operating cash flow	-762432	Operating Cash Flow: -762432 Open source
20232023-12-31	Operating cash flow	-550036	Operating Cash Flow: -550036 Open source
20242024-12-31	Operating cash flow	-423959	Operating Cash Flow: -423959 Open source
20252025-12-31	Operating cash flow	-1163964	Operating Cash Flow: -1163964 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -1.2M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-1359880	Operating Cash Flow: -1356498 Open source Capital Expenditure: 3382 Open source
20172017-12-31	Free cash flow	-1147460	Operating Cash Flow: -1138347 Open source Capital Expenditure: 9113 Open source
20182018-12-31	Free cash flow	Unavailable	Operating Cash Flow: -999949 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -743659 Open source
20202020-12-31	Free cash flow	-883991	Operating Cash Flow: -878086 Open source Capital Expenditure: 5905 Open source
20212021-12-31	Free cash flow	-1783512	Operating Cash Flow: -1744469 Open source Capital Expenditure: 39043 Open source
20222022-12-31	Free cash flow	-820425	Operating Cash Flow: -762432 Open source Capital Expenditure: 57993 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -550036 Open source
20242024-12-31	Free cash flow	Unavailable	Operating Cash Flow: -423959 Open source
20252025-12-31	Free cash flow	-1190016	Operating Cash Flow: -1163964 Open source Capital Expenditure: 26052 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

2,802.4% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	2,189.5%	Total Liabilities: 4691153 Open source Total Assets: 214257 Open source
20172017-12-31	Liabilities / assets	1,488.8%	Total Liabilities: 5799764 Open source Total Assets: 389570 Open source
20182018-12-31	Liabilities / assets	4,297.9%	Total Liabilities: 6078010 Open source Total Assets: 141417 Open source
20192019-12-31	Liabilities / assets	3,543.2%	Total Liabilities: 12040867 Open source Total Assets: 339832 Open source
20202020-12-31	Liabilities / assets	3,908.6%	Total Liabilities: 11795601 Open source Total Assets: 301786 Open source
20212021-12-31	Liabilities / assets	2,776.5%	Total Liabilities: 21657672 Open source Total Assets: 780022 Open source
20222022-12-31	Liabilities / assets	1,739.6%	Total Liabilities: 13132365 Open source Total Assets: 754913 Open source
20232023-12-31	Liabilities / assets	2,250%	Total Liabilities: 14408705 Open source Total Assets: 640397 Open source
20242024-12-31	Liabilities / assets	2,570.1%	Total Liabilities: 15407409 Open source Total Assets: 599495 Open source
20252025-12-31	Liabilities / assets	2,802.4%	Total Liabilities: 17447907 Open source Total Assets: 622601 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.03× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	0.04×	Current Assets: 185070 Open source Current Liabilities: 4648659 Open source
20172017-12-31	Current assets / current liabilities	0.06×	Current Assets: 357557 Open source Current Liabilities: 5799764 Open source
20182018-12-31	Current assets / current liabilities	0.02×	Current Assets: 115367 Open source Current Liabilities: 6026600 Open source
20192019-12-31	Current assets / current liabilities	0.01×	Current Assets: 57806 Open source Current Liabilities: 10989633 Open source
20202020-12-31	Current assets / current liabilities	0×	Current Assets: 55351 Open source Current Liabilities: 11482607 Open source
20212021-12-31	Current assets / current liabilities	0.03×	Current Assets: 533827 Open source Current Liabilities: 21140492 Open source
20222022-12-31	Current assets / current liabilities	0.03×	Current Assets: 333577 Open source Current Liabilities: 12700821 Open source
20232023-12-31	Current assets / current liabilities	0.02×	Current Assets: 314060 Open source Current Liabilities: 14171637 Open source
20242024-12-31	Current assets / current liabilities	0.02×	Current Assets: 374837 Open source Current Liabilities: 15267192 Open source
20252025-12-31	Current assets / current liabilities	0.03×	Current Assets: 459583 Open source Current Liabilities: 17311263 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 3.45 million Exact value Exact value: -3447613 USD 2016-01-01 – 2016-12-31: -3447613 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2016-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -3447613 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3447613 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843218000049/nphc-20171231.xml#299799 Filing: 000139843218000049 The citation records this snapshot. The page link may show a newer release later.	−USD 1.36 million Exact value Exact value: -1356498 USD 2016-01-01 – 2016-12-31: -1356498 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2016-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -1356498 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1356498 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843218000049/nphc-20171231.xml#304742 Filing: 000139843218000049 The citation records this snapshot. The page link may show a newer release later.	USD 3,382 Exact value Exact value: 3382 USD 2016-01-01 – 2016-12-31: 3382 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUTRA PHARMA CORP · 2016-12-31 NUTRA PHARMA CORP (edgar:1119643) Capital Expenditure: 3382 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3382 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843218000049/nphc-20171231.xml#305104 Filing: 000139843218000049 The citation records this snapshot. The page link may show a newer release later.	−USD 1.36 million Calculation and evidence -1356498 − 3382 USD Exact free cash flow: -1359880 USD 2016-01-01 – 2016-12-31: -1356498 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 3382 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NUTRA PHARMA CORP · 2016-12-31 NUTRA PHARMA CORP (edgar:1119643) Free cash flow: -1359880 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1356498 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843218000049/nphc-20171231.xml#304742 Filing: 000139843218000049 Input fundies:CapitalExpenditure: 3382 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843218000049/nphc-20171231.xml#305104 Filing: 000139843218000049 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 4.03 million Exact value Exact value: -4028748 USD 2017-01-01 – 2017-12-31: -4028748 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2017-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -4028748 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4028748 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843221000007/nphc-20181231.xml#352746 Filing: 000139843221000007 The citation records this snapshot. The page link may show a newer release later.	−USD 1.14 million Exact value Exact value: -1138347 USD 2017-01-01 – 2017-12-31: -1138347 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2017-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -1138347 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1138347 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843221000007/nphc-20181231.xml#358409 Filing: 000139843221000007 The citation records this snapshot. The page link may show a newer release later.	USD 9,113 Exact value Exact value: 9113 USD 2017-01-01 – 2017-12-31: 9113 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUTRA PHARMA CORP · 2017-12-31 NUTRA PHARMA CORP (edgar:1119643) Capital Expenditure: 9113 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9113 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843221000007/nphc-20181231.xml#358592 Filing: 000139843221000007 The citation records this snapshot. The page link may show a newer release later.	−USD 1.15 million Calculation and evidence -1138347 − 9113 USD Exact free cash flow: -1147460 USD 2017-01-01 – 2017-12-31: -1138347 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 9113 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NUTRA PHARMA CORP · 2017-12-31 NUTRA PHARMA CORP (edgar:1119643) Free cash flow: -1147460 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1138347 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843221000007/nphc-20181231.xml#358409 Filing: 000139843221000007 Input fundies:CapitalExpenditure: 9113 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000139843221000007/nphc-20181231.xml#358592 Filing: 000139843221000007 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 3.88 million Exact value Exact value: -3884695 USD 2018-01-01 – 2018-12-31: -3884695 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2018-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -3884695 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3884695 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315221015860/nhpc-20191231.xml#496752 Filing: 000149315221015860 The citation records this snapshot. The page link may show a newer release later.	−USD 999,949 Exact value Exact value: -999949 USD 2018-01-01 – 2018-12-31: -999949 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2018-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -999949 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -999949 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315221015860/nhpc-20191231.xml#514224 Filing: 000149315221015860 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 6.59 million Exact value Exact value: -6591442 USD 2019-01-01 – 2019-12-31: -6591442 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2019-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -6591442 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -6591442 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315221022204/nphc-20201231.xml#345355 Filing: 000149315221022204 The citation records this snapshot. The page link may show a newer release later.	−USD 743,659 Exact value Exact value: -743659 USD 2019-01-01 – 2019-12-31: -743659 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2019-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -743659 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -743659 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315221022204/nphc-20201231.xml#358483 Filing: 000149315221022204 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 769,184 Exact value Exact value: -769184 USD 2020-01-01 – 2020-12-31: -769184 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2020-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -769184 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -769184 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315222010035/form10-k.htm#1246919 Filing: 000149315222010035 The citation records this snapshot. The page link may show a newer release later.	−USD 878,086 Exact value Exact value: -878086 USD 2020-01-01 – 2020-12-31: -878086 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2020-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -878086 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -878086 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315222010035/form10-k.htm#1268219 Filing: 000149315222010035 The citation records this snapshot. The page link may show a newer release later.	USD 5,905 Exact value Exact value: 5905 USD 2020-01-01 – 2020-12-31: 5905 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUTRA PHARMA CORP · 2020-12-31 NUTRA PHARMA CORP (edgar:1119643) Capital Expenditure: 5905 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5905 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315222010035/form10-k.htm#1271032 Filing: 000149315222010035 The citation records this snapshot. The page link may show a newer release later.	−USD 883,991 Calculation and evidence -878086 − 5905 USD Exact free cash flow: -883991 USD 2020-01-01 – 2020-12-31: -878086 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 5905 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NUTRA PHARMA CORP · 2020-12-31 NUTRA PHARMA CORP (edgar:1119643) Free cash flow: -883991 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -878086 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315222010035/form10-k.htm#1268219 Filing: 000149315222010035 Input fundies:CapitalExpenditure: 5905 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315222010035/form10-k.htm#1271032 Filing: 000149315222010035 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 13.1 million Exact value Exact value: -13095521 USD 2021-01-01 – 2021-12-31: -13095521 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2021-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -13095521 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -13095521 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000164117225026446/form10-k.htm#1353641 Filing: 000164117225026446 The citation records this snapshot. The page link may show a newer release later.	−USD 1.74 million Exact value Exact value: -1744469 USD 2021-01-01 – 2021-12-31: -1744469 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2021-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -1744469 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1744469 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000164117225026446/form10-k.htm#1259045 Filing: 000164117225026446 The citation records this snapshot. The page link may show a newer release later.	USD 39,043 Exact value Exact value: 39043 USD 2021-01-01 – 2021-12-31: 39043 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUTRA PHARMA CORP · 2021-12-31 NUTRA PHARMA CORP (edgar:1119643) Capital Expenditure: 39043 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 39043 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000164117225026446/form10-k.htm#1262691 Filing: 000164117225026446 The citation records this snapshot. The page link may show a newer release later.	−USD 1.78 million Calculation and evidence -1744469 − 39043 USD Exact free cash flow: -1783512 USD 2021-01-01 – 2021-12-31: -1744469 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 39043 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NUTRA PHARMA CORP · 2021-12-31 NUTRA PHARMA CORP (edgar:1119643) Free cash flow: -1783512 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1744469 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000164117225026446/form10-k.htm#1259045 Filing: 000164117225026446 Input fundies:CapitalExpenditure: 39043 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000164117225026446/form10-k.htm#1262691 Filing: 000164117225026446 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	USD 8.18 million Exact value Exact value: 8176871 USD 2022-01-01 – 2022-12-31: 8176871 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2022-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: 8176871 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: 8176871 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315225024800/form10-k.htm#1264818 Filing: 000149315225024800 The citation records this snapshot. The page link may show a newer release later.	−USD 762,432 Exact value Exact value: -762432 USD 2022-01-01 – 2022-12-31: -762432 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2022-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -762432 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -762432 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315225024800/form10-k.htm#1167662 Filing: 000149315225024800 The citation records this snapshot. The page link may show a newer release later.	USD 57,993 Exact value Exact value: 57993 USD 2022-01-01 – 2022-12-31: 57993 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUTRA PHARMA CORP · 2022-12-31 NUTRA PHARMA CORP (edgar:1119643) Capital Expenditure: 57993 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 57993 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315225024800/form10-k.htm#1172958 Filing: 000149315225024800 The citation records this snapshot. The page link may show a newer release later.	−USD 820,425 Calculation and evidence -762432 − 57993 USD Exact free cash flow: -820425 USD 2022-01-01 – 2022-12-31: -762432 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 57993 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NUTRA PHARMA CORP · 2022-12-31 NUTRA PHARMA CORP (edgar:1119643) Free cash flow: -820425 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -762432 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315225024800/form10-k.htm#1167662 Filing: 000149315225024800 Input fundies:CapitalExpenditure: 57993 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315225024800/form10-k.htm#1172958 Filing: 000149315225024800 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 1.39 million Exact value Exact value: -1393356 USD 2023-01-01 – 2023-12-31: -1393356 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2023-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -1393356 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1393356 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226007044/form10-k.htm#1074643 Filing: 000149315226007044 The citation records this snapshot. The page link may show a newer release later.	−USD 550,036 Exact value Exact value: -550036 USD 2023-01-01 – 2023-12-31: -550036 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2023-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -550036 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -550036 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226007044/form10-k.htm#1095421 Filing: 000149315226007044 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	−USD 1.29 million Exact value Exact value: -1285663 USD 2024-01-01 – 2024-12-31: -1285663 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2024-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -1285663 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -1285663 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1024415 Filing: 000149315226024641 The citation records this snapshot. The page link may show a newer release later.	−USD 423,959 Exact value Exact value: -423959 USD 2024-01-01 – 2024-12-31: -423959 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2024-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -423959 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -423959 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1045971 Filing: 000149315226024641 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2025 2025-01-01 – 2025-12-31	−USD 2.05 million Exact value Exact value: -2047392 USD 2025-01-01 – 2025-12-31: -2047392 USD Inspect Net Income Open source Share or cite Citation for Net Income · NUTRA PHARMA CORP · 2025-12-31 NUTRA PHARMA CORP (edgar:1119643) Net Income: -2047392 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2047392 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1024047 Filing: 000149315226024641 The citation records this snapshot. The page link may show a newer release later.	−USD 1.16 million Exact value Exact value: -1163964 USD 2025-01-01 – 2025-12-31: -1163964 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · NUTRA PHARMA CORP · 2025-12-31 NUTRA PHARMA CORP (edgar:1119643) Operating Cash Flow: -1163964 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1163964 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1045508 Filing: 000149315226024641 The citation records this snapshot. The page link may show a newer release later.	USD 26,052 Exact value Exact value: 26052 USD 2025-01-01 – 2025-12-31: 26052 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · NUTRA PHARMA CORP · 2025-12-31 NUTRA PHARMA CORP (edgar:1119643) Capital Expenditure: 26052 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 26052 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1047505 Filing: 000149315226024641 The citation records this snapshot. The page link may show a newer release later.	−USD 1.19 million Calculation and evidence -1163964 − 26052 USD Exact free cash flow: -1190016 USD 2025-01-01 – 2025-12-31: -1163964 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 26052 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · NUTRA PHARMA CORP · 2025-12-31 NUTRA PHARMA CORP (edgar:1119643) Free cash flow: -1190016 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T16:28:38Z Snapshot: 39d9c1bca74bb8c17cd7b6ce1d7b5afa75fce0ea251f3f7d8fc69fdbd9abb28f Dimensions: Consolidated View: https://fundies.io/companies/edgar/1119643?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1163964 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1045508 Filing: 000149315226024641 Input fundies:CapitalExpenditure: 26052 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1119643/000149315226024641/form10-k.htm#1047505 Filing: 000149315226024641 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

127 filings · 4,041 latest values · 4,041 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001119643, 1119643, NPHC, edgar:1119643, nphc

Also known as CYBER VITAMIN COM, NUTRA PHARMA CORP., NUTRA PHARMA CORP, NUTRA PHARMA CORP.

NUTRA PHARMA CORP

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation